ライフサイエンスコーパス: genital herpes

1 ype 2 infection in mice and earlier onset of genital herpes.

2 s is an uncommon but serious complication of genital herpes.

3 quisition among patients with newly acquired genital herpes.

4 kin-lesion biopsy samples from subjects with genital herpes.

5 by showing that CVL samples prevented murine genital herpes.

6 ced significant protection against recurrent genital herpes.

7 inoculation was examined in a mouse model of genital herpes.

8 also become commonly associated with primary genital herpes.

9 d monthly for clinical signs and symptoms of genital herpes.

10 the reduction in transmission of symptomatic genital herpes.

11 e for a role for IFI16 in protection against genital herpes.

12 ritical in developing effective vaccines for genital herpes.

13 counseling the patient with newly diagnosed genital herpes.

14 ans is vital for improving the management of genital herpes.

15 tic vaccine would help control the spread of genital herpes.

16 ns (84.7%) had never received a diagnosis of genital herpes.

17 ose regular sexual partners had a history of genital herpes.

18 ts and providers about care of patients with genital herpes.

19 was evaluated using the guinea pig model of genital herpes.

20 viral therapies for the control of recurrent genital herpes.

21 nto a candidate vaccine strain for HSV-2 and genital herpes.

22 even in subjects with no reported history of genital herpes.

23 ccinated persons who did and did not develop genital herpes.

24 well tolerated for suppression of recurrent genital herpes.

25 equire suppressive therapy for management of genital herpes.

26 ted in animal models of recurrent ocular and genital herpes.

27 sma genitalium, and no cure is available for genital herpes.

28 No cure is available for genital herpes.

29 ll therapeutic vaccine strategy in combating genital herpes.

30 , Mycoplasma genitalium, trichomoniasis, and genital herpes.

31 reduced frequency and severity of recurrent genital herpes.

32 individuals aged 15 to 49 years, living with genital herpes.

33 ased the severity and frequency of recurrent genital herpes.

34 rce (USPSTF) recommendation on screening for genital herpes.

35 bility is central to preventing and treating genital herpes.

36 on, and their reactivation leads to oral and genital herpes.

37 n adjuvant failed to show protection against genital herpes.

38 coprotein D (gD2) subunit vaccine to prevent genital herpes.

39 nner in otherwise healthy men and women with genital herpes.

40 ng potentiates the susceptibility of mice to genital herpes.

41 ht new strategies for vaccine design against genital herpes.

42 n the progesterone-induced B6 mouse model of genital herpes.

43 , including HSV type 2 (HSV-2), which causes genital herpes.

44 atic" vaccine against ocular, orofacial, and genital herpes.

45 tions for treatment of episodes of recurrent genital herpes.

46 of ASP2151 for episodic therapy of recurrent genital herpes.

47 between those patients with mild vs. severe genital herpes (1 in 3,800 vs. 1 in 6,600, P > .5).

48 930), trichomoniasis (1 study; n = 779), and genital herpes (1 study; n = 779).

49 ) 57 women at 70 clinic visits with clinical genital herpes; (2) 39 of the same women at 46 clinic vi

50 follow-up visit: trichomoniasis in 23 (18%); genital herpes, 20 (12%); gonorrhea, 9 (7%); syphilis, 7

51 roid, 29% had syphilitic ulcers, and 10% had genital herpes; 32% of the ulcer specimens were M-PCR ne

52 e 53 subjects who had no reported history of genital herpes, 33 (62 percent) subsequently reported ha

53 Chancroid (80%), syphilis (8%), and genital herpes (8%) were the most frequent diagnoses.

54 oniasis in 16 women (11%); syphilis, 9 (6%); genital herpes, 8 (6%); gonorrhea, 5 (4%); chlamydia, 5

55 ce partners were followed for recurrences of genital herpes; 89 were enrolled in a substudy of HSV-2

56 common as HSV-2 in causing first episodes of genital herpes, a disease that is associated with an inc

57 and B vaccine in the treatment of recurrent genital herpes, a randomized, placebo-controlled trial w

58 ls of protection against acute and recurrent genital herpes after vaginal challenge with wild-type vi

59 ficantly reduces the risk of transmission of genital herpes among heterosexual, HSV-2-discordant coup

60 f recurrent cold sores on the lips and face, genital herpes, among other diseases.

61 To examine the risks of genital herpes and antiherpes treatment during pregnancy

62 In a cohort of patients with genital herpes and healthy controls, the minor G allele

63 afforded by gD2/AS04 against HSV-1 and HSV-2 genital herpes and investigated whether immunization cou

64 ex virus type 2 (HSV-2) is the cause of most genital herpes and is almost always sexually transmitted

65 Prevention of genital herpes and other sexually transmitted infections

66 e mechanisms of protection against recurrent genital herpes and promote the tegument RR2 protein as a

67 T(RM) cells in protection against recurrent genital herpes and promotes the RR2-based subunit therap

68 e of infection and the severity of recurrent genital herpes and propose the novel prime-pull vaccine

69 s and the VM in protection against recurrent genital herpes and propose the prime-pull therapeutic va

70 be aware of the subclinical presentation of genital herpes and the potential these patients have for

71 rat may provide an excellent model to study genital herpes and to evaluate preventive strategies.

72 d 11 with HSV-2 antibodies but no history of genital herpes) and obtained daily swabs for viral cultu

73 e human pathogens that can cause cold sores, genital herpes, and blindness.

74 ects (72 percent) who reported no history of genital herpes, and HSV DNA was detected by the polymera

75 mitted infectious diseases, such as AIDS and genital herpes, and may have immunological effects.

76 e the cause of herpes labialis (cold sores), genital herpes, and sight-impairing keratitis.

77 HSV-2 but who reported having no history of genital herpes, and we compared their patterns of viral

78 The frequency of viral shedding in men with genital herpes appears comparable with that in women.

79 study, 52 patients with frequently recurrent genital herpes applied topical resiquimod gel 0.01% (twi

80 studies of the long-term clinical course of genital herpes are available.

81 cines against human papillomavirus (HPV) and genital herpes are in the final stages of testing.

82 monitored couples, most persons who transmit genital herpes are not aware of having the infection.

83 of subjects who did not have a recurrence of genital herpes at 6 months was 65% among valacyclovir re

84 ur HSV-2-seropositive women with symptomatic genital herpes attended a clinic daily during a 30-day p

85 c interaction between HIV-1 transmission and genital herpes being of special concern for control of b

86 Herpes simplex virus 1 and 2 cause genital herpes, blindness, encephalitis, and occasionall

87 microbicide and/or therapeutic agent against genital herpes by increasing resistance to HSV-2 and enh

88 Genital herpes can be caused by herpes simplex virus 2 (

89 cubation period and most persons who acquire genital herpes can identify the transmitting partner, a

90 Recently, the number of reported genital herpes cases caused by type 1 virus has increase

91 Africa region, the 3.9 million seroprevalent genital herpes cases from 2020 to 2030 contributed to US

92 Not only does genital herpes cause painful, recurrent symptoms, it is

93 ence of HSV-1 decreased but the incidence of genital herpes caused by HSV-1 may be increasing.

94 Genital herpes, caused by herpes simplex virus (HSV) typ

95 Genital herpes, caused by herpes simplex virus, is the m

96 pDCs are critical in innate defense against genital herpes challenge, adaptive Th1 immunity develope

97 neurotropic infections such as cutaneous and genital herpes, chickenpox, and shingles.

98 ACIDFORM protected 21 (81%) of 26 mice from genital herpes, compared with 3 (12%) of 25 mice who rec

99 pants whose partners disclosed that they had genital herpes, compared with participants whose partner

100 ia, and a trend for less acute and recurrent genital herpes, compared with the gD2 vaccines.

101 In the 90 LMICs, genital herpes contributed to US$813.5 million in treatm

102 anatomical locations may be responsible for genital herpes control in chronically infected individua

103 An effective vaccine for the prevention of genital herpes could help control this epidemic.

104 women were classified into 3 groups based on genital herpes diagnosis and treatment: genital herpes w

105 The primary end point was occurrence of genital herpes disease due to either HSV-1 or HSV-2 from

106 The primary end point was the occurrence of genital herpes disease in all subjects in Study 1 and in

107 lum and monophosphoryl lipid A (MPL) reduced genital herpes disease in HSV-1-seronegative women but n

108 A prophylactic vaccine for genital herpes disease remains an elusive goal.

109 ationships between these cells and recurrent genital herpes disease severity in the general populatio

110 iviral drugs in the treatment and control of genital herpes disease.

111 confidence interval [CI], -29 to 50) against genital herpes disease.

112 irus titers; 3) had decreased overt signs of genital herpes disease; and 4) did not succumb to lethal

113 pared with being unexposed, having untreated genital herpes during first or second trimester was asso

114 The acquisition of genital herpes during pregnancy has been associated with

115 Time since first genital herpes episode was significantly associated with

116 ns from 118 patients with culture-documented genital herpes episodes, and their results were compared

117 n may influence the epidemiology of clinical genital herpes, even if prior HSV-1 infection does not p

118 and 14 were given an incorrect diagnosis of genital herpes, for a ratio of true positive results to

119 ither the murine nor the guinea pig model of genital herpes fully recapitulates human disease.

120 The spectrum of genital herpes (GH) has been understudied in men, especi

121 An effective vaccine for genital herpes has been difficult to achieve because of

122 le HP inhibitors (HPIs) for the treatment of genital herpes has been hindered by the lack of structur

123 infections (STI), but diagnostic methods for genital herpes have not kept pace with the movement towa

124 Current therapies for genital herpes have only partial efficacy.

125 as vaginalis infection, primary or recurrent genital herpes, having bacterial vaginosis by Nugent cri

126 Of 11 HSV-2-seropositive men without a genital herpes history, 7 recognized typical recurrences

127 Fourteen of 15 mice were protected from genital herpes if they were challenged with HSV-2 pretre

128 accine strategy to protect against recurrent genital herpes.IMPORTANCEThe present study investigates

129 Herpes simplex virus 2 (HSV2) causes genital herpes in >400 million persons worldwide.

130 rcentage reported having been diagnosed with genital herpes in 1999-2004 compared with 1988-1994 (1.8

131 d economic and quality-of-life losses due to genital herpes in 2019, in 90 LMICs, and from 2020 to 20

132 1 genital herpes was less than that of HSV-2 genital herpes in cotton rats, and yet the model allowed

133 virus entry molecules have failed to prevent genital herpes in human trials.

134 ay be useful in the treatment and control of genital herpes in humans.

135 HSV-1 is an increasingly important cause of genital herpes in industrialized countries.

136 Economic losses due to genital herpes in LMICs can be large, especially when co

137 HSV-1) is the leading cause of first-episode genital herpes in many countries.

138 translated to significant protection against genital herpes in mice treated with 0.1% griffithsin gel

139 However, unlike partners with genital herpes in prospectively monitored couples, most

140 more, HSV-1 has become an important cause of genital herpes in some developed countries.

141 ng in the genital mucosal epithelium causing genital herpes in symptomatic patients.

142 her efficacy against HSV-1 compared to HSV-2 genital herpes in the novel DMPA-synchronized cotton rat

143 t on the frequency and severity of recurrent genital herpes in the recurrent herpes guinea pig model.

144 rmine whether PRO 2000 could protect against genital herpes in vivo.

145 glycoprotein D vaccine has efficacy against genital herpes in women who are seronegative for both HS

146 ncreasing evidence that sexually transmitted genital herpes increases HIV acquisition, and the reacti

147 In addition, genital herpes increases the frequency of HIV infection

148 Genital herpes increases the risk of transmission and ac

149 to estimate the prevalence and incidence of genital herpes infection and to assess the relation betw

150 vealed increased risk of PTD associated with genital herpes infection if left untreated and a potenti

151 d effective for the suppression of recurrent genital herpes infection in HIV-infected individuals.

152 l and pathophysiological features typical of genital herpes infection in humans, including the produc

153 Here, using genital herpes infection in mice, we show that primary i

154 aginal mucosa and provide protection against genital herpes infection in mice.

155 ulcers caused by HSV-2, which suggests that genital herpes infection likely increases the efficiency

156 rpes medications in mitigating the effect of genital herpes infection on the risk of PTD.

157 guidelines, key questions for management of genital herpes infection were developed with a panel of

158 A vaccine that prevents genital herpes infection will have major public health b

159 poly I:C has been shown to protect mice from genital herpes infection, the mechanism by which these a

160 Using a mouse model of genital herpes infection, we demonstrate that both antib

161 tablished, these cells protect hosts against genital herpes infection.

162 who were seropositive reported a history of genital herpes infection.

163 uce vaginal inflammation in a mouse model of genital herpes infection.

164 (endocervix and ectocervix/vagina) to mimic genital herpes infections caused by herpes simplex virus

165 ntibody can provide passive immunity against genital herpes infections in mice; orally administered p

166 The proportion of HSV-1 among initial genital herpes infections was higher among men who had s

167 latform against primary and secondary female genital herpes infections.

168 simplex virus 1 (HSV-1), a leading cause of genital herpes, infects oral or genital mucosal epitheli

169 ing that the vaccine protected against HSV-1 genital herpes instead.

170 s to HSV-2 of 22% in the general population, genital herpes is 1 of the 3 most prevalent sexually tra

171 Genital herpes is a common sexually transmitted infectio

172 Genital herpes is a highly prevalent chronic disease cau

173 Importance: Genital herpes is a prevalent sexually transmitted infec

174 Genital herpes is an incurable, chronic disease that aff

175 sions and Relevance: Serologic screening for genital herpes is associated with a high rate of false-p

176 Most genital herpes is caused by HSV-2, although HSV-1 accoun

177 peutic mucosal vaccines.IMPORTANCE Recurrent genital herpes is one of the most common sexually transm

178 entral issue in the public health problem of genital herpes is the high proportion of genital HSV inf

179 Genital herpes is the main cause of genital ulcers world

180 In many developing countries genital herpes is untreated, and in the United States on

181 , the principal causative agent of recurrent genital herpes, is a highly prevalent viral infection wo

182 We studied the persistence of genital herpes lesion-derived HSV-specific CD8+ CTL from

183 Application of resiquimod to genital herpes lesions appeared to reduce the frequency

184 elivery, the standard of care for women with genital herpes lesions at the time of delivery, reduces

185 In genital herpes lesions, the superficial layers of strati

186 both the severity and frequency of recurrent genital herpes lesions.

187 -2 gD2 antigen protected guinea pigs against genital herpes, limiting primary infection and reducing

188 interventions more specifically tailored to genital herpes may be useful and should be an important

189 DCs in the skin during primary or recurrent genital herpes may enhance HIV-1 infection of adjacent D

190 recognition by physicians that patients with genital herpes may have expert knowledge.

191 lines in HSV-2 infections, the prevalence of genital herpes may increase.

192 ositive for HSV-2 only reported a history of genital herpes more frequently (16.2%) than persons sero

193 valuated in primary culture systems and in a genital herpes murine model.

194 ies suggest that most sexual transmission of genital herpes occurs when persons shed virus but lack l

195 ficacy, in the guinea pig model of recurrent genital herpes, of subunit vaccine candidates that were

196 ficacy, in the guinea pig model of recurrent genital herpes, of subunit vaccine candidates that were

197 rica have measured the unfavorable effect of genital herpes on infected patients, health care resourc

198 The patient's genital herpes outbreaks were not controlled by high-dos

199 screening, harms of screening, reduction in genital herpes outbreaks.

200 hough HSV-2 remained the predominant type of genital herpes, over the 6-year span of this study, ther

201 The significant gap in knowledge on genital herpes pathogenesis has been further highlighted

202 in the prevalence of Incurable STDs (such as genital herpes); perhaps greater Importance of symptomat

203 ects with no prior history of oral/labial or genital herpes possessed HSV-specific T cell immunity bu

204 HSV-1 prevalence and ever-symptomatic HSV-1 genital herpes prevalence.

205 We evaluated a genital herpes prophylactic vaccine containing herpes si

206 of 145 persons who had the severity of their genital herpes quantified through determination of their

207 The time to first genital herpes recurrence was significantly shorter in t

208 HIV+ patients who suffered more severe genital herpes recurrences had significantly lower HSV-s

209 ltured blood mononuclear cells and decreased genital herpes recurrences in an animal model.

210 We estimated genital herpes-related spending on treatment, wage losse

211 The mouse model of genital herpes relies on medoxyprogesterone treatment of

212 e mechanisms of protection against recurrent genital herpes remain to be fully elucidated.

213 g a partner who disclosed that he or she had genital herpes remained a strong protective factor again

214 , eliminating or at least reducing recurrent genital herpes remains a challenge.

215 nglia (DRG) to cause recurrent orofacial and genital herpes, respectively.

216 onsible for herpes labialis (cold sores) and genital herpes, respectively.

217 Efforts to prevent genital herpes should begin at an early age.

218 Genital herpes simplex is one of the most prevalent sexu

219 Visits to physicians for genital herpes simplex virus (HSV) infection continue to

220 Importance: Genital herpes simplex virus (HSV) infection is a preval

221 Primary genital herpes simplex virus (HSV) infection is commonly

222 Genital herpes simplex virus (HSV) reactivation is thoug

223 he efficacy of valacyclovir and acyclovir on genital herpes simplex virus (HSV) shedding was assessed

224 n 500 million people are estimated to have a genital herpes simplex virus (HSV-2) infection.

225 Attempts to develop a vaccine to prevent genital herpes simplex virus 2 (HSV-2) disease have been

226 Patients with newly acquired genital herpes simplex virus 2 (HSV-2) infection have vi

227 e epidemiological studies have reported that genital herpes simplex virus 2 (HSV-2) infection increas

228 study assessed 79 men (63 with a history of genital herpes simplex virus [HSV] type 2 infection, 5 w

229 Genital herpes simplex virus infections are widespread t

230 wice daily) for the suppression of recurrent genital herpes simplex virus infections in human immunod

231 Following genital herpes simplex virus type 2 (HSV-2) exposure, NK

232 icient (CXCL10(-/-)) mice which succumbed to genital herpes simplex virus type 2 (HSV-2) infection an

233 Genital herpes simplex virus type 2 (HSV-2) infection ca

234 min) relative to host immune defense against genital herpes simplex virus type 2 (HSV-2) infection ha

235 investigated the mechanism of resistance to genital herpes simplex virus type 2 (HSV-2) infection in

236 Clinical and virologic manifestations of genital herpes simplex virus type 2 (HSV-2) infection va

237 e vaccines are effective in animal models of genital herpes simplex virus type 2 (HSV-2) infection.

238 n = 188) from 29 patients with first-episode genital herpes simplex virus type 2 (HSV-2) infections w

239 Effective vaccines against genital herpes simplex virus type 2 (HSV-2) may need to

240 Using a mouse model for genital herpes simplex virus type 2 infection, we find t

241 The clinical severity of genital herpes simplex virus-2 (HSV-2) infection varies

242 In a mouse model of genital herpes simplex virus-2 (HSV-2) infection, which

243 both the severity and frequency of recurrent genital herpes sores.

244 persons without past or current symptoms of genital herpes; studies evaluating accuracy and harms of

245 ter adjustment for sex, HSV type 1, oral and genital herpes symptoms, immigrant status, and the inter

246 m DRG and reducing the severity of recurrent genital herpes, the mechanisms for recruiting these T ce

247 ns with laboratory-documented newly acquired genital herpes, the median duration of the sexual relati

248 le candidate Ag to be incorporated in future genital herpes therapeutic mucosal vaccines.IMPORTANCE R

249 In spite of the high health burden of genital herpes, there is still no effective intervention

250 mptomatic but nevertheless fail to recognize genital herpes; they serve as reservoirs for transmissio

251 umber of persons have learned that they have genital herpes through serologic testing.

252 156 HSV-2-positive persons with a history of genital herpes to receive one of four doses of oral prit

253 gnancy events, including vaginal infections, genital herpes, urinary tract infections (UTIs), and oth

254 accine strategy to protect against recurrent genital herpes using the latently infected guinea pig mo

255 Thus, an effective genital herpes vaccine would be an important weapon in t

256 olunteers entering trials of investigational genital herpes vaccines, 6 of the 24 immunocompetent sub

257 inical diagnosis of syphilis, chancroid, and genital herpes was 93%, 53%, and 0% and specificity was

258 Serologic screening for genital herpes was associated with psychosocial harms, i

259 of valaciclovir for suppression of recurrent genital herpes was conducted among 1479 immunocompetent

260 The severity of HSV-1 genital herpes was less than that of HSV-2 genital herpe

261 for bacterial vaginosis, trichomoniasis, and genital herpes was performed in a high-prevalence popula

262 in the subjects with no reported history of genital herpes was similar to that in the subjects with

263 tage who reported having been diagnosed with genital herpes was statistically different (14.3% in 199

264 Using a mouse model of genital herpes, we found that HSV-1-infection-associated

265 Persons with genital herpes were randomized into 3 dose cohorts to re

266 clinical trial of a subunit vaccine against genital herpes were recently reported.

267 Signs and symptoms of genital herpes were recorded by the participants and cli

268 plex virus 2 (HSV-2) is the primary cause of genital herpes, which is one of the most common sexually

269 treatment: genital herpes without treatment, genital herpes with antiherpes treatment, and no herpes

270 d on genital herpes diagnosis and treatment: genital herpes without treatment, genital herpes with an

271 ikely plays a role in the epidemic spread of genital herpes worldwide.